These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 29882016)

  • 41. A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours.
    Schram AM; Gandhi L; Mita MM; Damstrup L; Campana F; Hidalgo M; Grande E; Hyman DM; Heist RS
    Br J Cancer; 2018 Dec; 119(12):1471-1476. PubMed ID: 30425349
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer.
    Britten CD; Adjei AA; Millham R; Houk BE; Borzillo G; Pierce K; Wainberg ZA; LoRusso PM
    Invest New Drugs; 2014 Jun; 32(3):510-7. PubMed ID: 24395457
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Resistance of hepatocellular carcinoma to sorafenib can be overcome with co-delivery of PI3K/mTOR inhibitor BEZ235 and sorafenib in nanoparticles.
    Wu B; Li A; Zhang Y; Liu X; Zhou S; Gan H; Cai S; Liang Y; Tang X
    Expert Opin Drug Deliv; 2020 Apr; 17(4):573-587. PubMed ID: 32056461
    [No Abstract]   [Full Text] [Related]  

  • 44. Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer.
    Ring A; Wheatley D; Hatcher H; Laing R; Plummer R; Uttenreuther-Fischer M; Temple G; Pelling K; Schnell D
    Clin Cancer Res; 2015 Jun; 21(12):2737-44. PubMed ID: 25370464
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma.
    Harding JJ; Do RK; Yaqubie A; Cleverly A; Zhao Y; Gueorguieva I; Lahn M; Benhadji KA; Kelley RK; Abou-Alfa GK
    Cancer Med; 2021 May; 10(9):3059-3067. PubMed ID: 33811482
    [TBL] [Abstract][Full Text] [Related]  

  • 46. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Synergistic inhibition of colon cancer cell growth with nanoemulsion-loaded paclitaxel and PI3K/mTOR dual inhibitor BEZ235 through apoptosis.
    Zou H; Li L; Garcia Carcedo I; Xu ZP; Monteiro M; Gu W
    Int J Nanomedicine; 2016; 11():1947-58. PubMed ID: 27226714
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors.
    Mehnert JM; Edelman G; Stein M; Camisa H; Lager J; Dedieu JF; Ghuysen AF; Sharma J; Liu L; LoRusso PM
    Invest New Drugs; 2018 Feb; 36(1):36-44. PubMed ID: 28417284
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase I study of TAS-115, a novel oral multi-kinase inhibitor, in patients with advanced solid tumors.
    Doi T; Matsubara N; Kawai A; Naka N; Takahashi S; Uemura H; Yamamoto N
    Invest New Drugs; 2020 Aug; 38(4):1175-1185. PubMed ID: 31820255
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
    Xia A; Li H; Li R; Lu L; Wu X
    Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer.
    Tolaney S; Burris H; Gartner E; Mayer IA; Saura C; Maurer M; Ciruelos E; Garcia AA; Campana F; Wu B; Xu Y; Jiang J; Winer E; Krop I
    Breast Cancer Res Treat; 2015 Jan; 149(1):151-61. PubMed ID: 25537644
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer-results of a first-in-man dose-escalation study with a fixed-dose extension phase.
    Isambert N; Delord JP; Soria JC; Hollebecque A; Gomez-Roca C; Purcea D; Rouits E; Belli R; Fumoleau P
    Ann Oncol; 2015 May; 26(5):1005-1011. PubMed ID: 25646368
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies.
    Awan FT; Gore L; Gao L; Sharma J; Lager J; Costa LJ
    Br J Haematol; 2016 Oct; 175(1):55-65. PubMed ID: 27293194
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors.
    Hong DS; Bowles DW; Falchook GS; Messersmith WA; George GC; O'Bryant CL; Vo AC; Klucher K; Herbst RS; Eckhardt SG; Peterson S; Hausman DF; Kurzrock R; Jimeno A
    Clin Cancer Res; 2012 Aug; 18(15):4173-82. PubMed ID: 22693357
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors.
    Shapiro GI; McCallum S; Adams LM; Sherman L; Weller S; Swann S; Keer H; Miles D; Müller T; Lorusso P
    Invest New Drugs; 2013 Jun; 31(3):742-50. PubMed ID: 23054208
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors.
    Puzanov I; Lindsay CR; Goff L; Sosman J; Gilbert J; Berlin J; Poondru S; Simantov R; Gedrich R; Stephens A; Chan E; Evans TR
    Clin Cancer Res; 2015 Feb; 21(4):701-11. PubMed ID: 25212606
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer.
    Kondo S; Tajimi M; Funai T; Inoue K; Asou H; Ranka VK; Wacheck V; Doi T
    Invest New Drugs; 2020 Dec; 38(6):1836-1845. PubMed ID: 32578154
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
    Bendell JC; Rodon J; Burris HA; de Jonge M; Verweij J; Birle D; Demanse D; De Buck SS; Ru QC; Peters M; Goldbrunner M; Baselga J
    J Clin Oncol; 2012 Jan; 30(3):282-90. PubMed ID: 22162589
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies.
    Gupta S; Argilés G; Munster PN; Hollebecque A; Dajani O; Cheng JD; Wang R; Swift A; Tosolini A; Piha-Paul SA
    Clin Cancer Res; 2015 Dec; 21(23):5235-44. PubMed ID: 26187616
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer.
    Jhaveri K; Wang R; Teplinsky E; Chandarlapaty S; Solit D; Cadoo K; Speyer J; D'Andrea G; Adams S; Patil S; Haque S; O'Neill T; Friedman K; Esteva FJ; Hudis C; Modi S
    Breast Cancer Res; 2017 Aug; 19(1):89. PubMed ID: 28764748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.